Stock GIMB GIMV NV
Add to a list
To use this feature you must be a member
Log inSign up

News Gimv NV

Equities

GIMB

BE0003699130

Investment Management & Fund Operators

Market Closed - Euronext Bruxelles
Other stock markets
 11:35:52 2024-11-29 am EST 		5-day change 1st Jan Change
40.55 EUR +1.38% Intraday chart for Gimv NV -0.73% -8.47%
Nov. 20 Gimv: majority stake sold in rehaneo CF
Nov. 20 Gimv Sells Majority Stake in Outpatient Rehabilitation Company MT

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Gimv : Half year figures
Nov. 21
 PU
Gimv : Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Nov. 21
 PU
Gimv: majority stake sold in rehaneo
Nov. 20
 CF
Gimv Sells Majority Stake in Outpatient Rehabilitation Company
Nov. 20
 MT
Gimv : sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
Nov. 20
 PU
Fremman Limited agreed to acquire an unknown majority stake in rehaneo GmbH from Gimv NV.
Nov. 19
 CI
Gimv NV Reports Earnings Results for the Half Year Ended September 30, 2024
Nov. 19
 CI
Gimv : participates in a $92M Series A financing round at Kivu Bioscience to advance next gen antibody drug conjugates
Oct. 28
 PU
Kivu Bioscience announced that it has received $92.000004 million in funding from a group of investors
Oct. 27
 CI
Gimv Sells United Dutch Breweries to Brouwerij Martens
Oct. 16
 MT
Gimv : Brouwerij Martens acquires United Dutch Breweries with a purpose of further joint global expansion
Oct. 16
 PU
The Martens Brewery of Bocholt acquired United Dutch Breweries B.V. from Gimv NV and management.
Oct. 15
 CI
Gimv : Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease
Oct. 15
 PU
Gimv: half of Infravest transferred to WorxInvest
Sep. 20
 CF
Belgium's Gimv to Sell Half of Infravest Stake to WorxInvest
Sep. 20
 MT
Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Sep. 19
 PU
Gimv : ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
Sep. 18
 PU
Gimv : ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
Sep. 17
 PU
Gimv : Biotalys granted patents for EVOCA in both Europe and the US
Sep. 17
 PU
ImmunOs Therapeutics AG announced that it has received $11 million in funding from Gimv NV, Pfizer Venture Investments LLC, Mission BioCapital, LP, BioMedPartners AG, Double Point Ventures, and other investors
Sep. 16
 CI
Kivu Bioscience announced that it expects to receive $93.721047 million in funding
Sep. 12
 CI
Such a long wait
Sep. 05
Our Logo
Gimv: sale of stake in Mega International
Sep. 05
 CF
Belgium's Gimv Divests Stake in Mega International to Bizzdesign
Sep. 05
 MT
Gimv : sells stake in Mega International to Bizzdesign, establishing a strong leadership position in the Enterprise Architecture and Digital Transformation space
Sep. 05
 PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GIMB Stock
  4. News Gimv NV
LAST HOURS | BLACK FRIDAY -40%: Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW